. 2014 Dec 1;125(5):784–792. doi: 10.1182/blood-2014-07-592881

Table 2.

Disease status before and following HSCT with aNK-DLI

Patient no.	Diagnosis	Prior chemotherapy regimens	EPOCH-F cycles received	Disease status			Time to progression post-HSCT (d)	Survival post-HSCT (mo)
Patient no.	Diagnosis	Prior chemotherapy regimens	EPOCH-F cycles received	Enrollment	Pre-HSCT	Best response post-HSCT	Time to progression post-HSCT (d)	Survival post-HSCT (mo)
1	DSRCT	3	1	AD	SD	SD	102	6.2
2	EWS	5	1	AD	PD	SD	55	5.6
3	DSRCT	3	3	AD	PR	CR	No relapse	8.5
4	EWS	4	3	NED	CR	CR	No relapse	27.4^*
5	DSRCT	2	2	AD	SD	CR	86	26.5^*
6	RMS	2	1	NED	CR	CR	79	10.4
7	EWS	3	3	AD	CR	CR	92	19.7^*
8	EWS	2	3	AD	CR	CR	187	10.2
9	EWS	2	3	NED	CR	CR	No relapse	12.5^*

Gray rows highlight patients who developed aGVHD.

Still alive.

AD, active disease; CR, complete remission with no evidence of disease; DSRCT, desmoplastic small round cell tumor; EWS, Ewing sarcoma; RMS: Rhabdomyosarcoma. NED, no evidence of disease; PD, progressive disease; PR, partial remission with residual active disease; SD, stable active disease.